


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the present application.

1. (currently amended) A compound according to formula (I)




(I)

wherein the compound of formula (I) is selected from the group of (i) and (ii)

wherein (i) comprises

~~X³ is (HO)₂PO—Z¹;~~
~~one or both of X¹ and X² is R¹—Y¹—A with each being the same or different, or optionally one of X¹ and X² is H;~~
~~A is either a direct link, (CH₂)_k with k being an integer from 0 to 30, or O;~~
~~Y¹ is (CH₂)_l with l being an integer from 1 to 30, —O—, —S—, —O—~~
~~—O—~~
~~||~~
~~C—, or NR²—;~~
~~Z¹ is (CH₂)_m or O(CH₂)_m with m being an integer from 1 to 50, C(R³)H, NH, O, or S;~~
~~Q¹ and Q² are independently H₂, =NR⁴, =O, or a combination of H and NR⁵R⁶;~~
~~R¹, for each of X¹ and X², is independently hydrogen, a straight or branched chain C1 to C30 alkyl, a straight or branched chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acetyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched chain C1 to C30 alkyl, an aryloxyalkyl including straight or branched chain C1 to C30 alkyl,~~



$R^2, R^3, R^4, R^5, R^6, R^7$, and R^8 are independently hydrogen, a straight or branched chain C1 to C30 alkyl, a straight or branched chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched chain C1 to C30 alkyl, or an aryloxyalkyl including straight or branched chain C1 to C30 alkyl;

wherein (ii) comprises

X^1 is $(HO)_2PO-Z^1-$;

~~one or both of X^2 and X^3~~ are both $R^1R^2N-R^4-Y^4-A$ with each being the same or different or optionally one of X^2 and X^3 is H;


A is either a direct link, $(CH_2)_k$ with k being an integer from 0 to 30, or Q;

Y^4 is $(CH_2)_l$ with l being an integer from 1 to 30, —O—, —S—, —O—
||
—C—, or —NR²—;

Z^1 is $-(CH_2)_m-$ or $-O(CH_2)_m-$ with m being an integer from 1 to 50, $-C(R^3)H-$, —NH—, or —O—, or —S—;

Q^1 and Q^2 are independently H_2 , $=NR^4$, $=O$, a combination of H and $-NR^5R^6$;

R^1 , for each of at X^2 or X^3 , is independently hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain C1 to C30 alkyl, an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl,



R^1 at X^3 is hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, or an acyl including a C1 to C30 alkyl or an aromatic or heteroaromatic ring; and

R^2 , R^3 , R^4 , R^5 , and R^6 , R^7 , and R^8 are independently hydrogen, a straight or branched-chain C1 to C30 alkyl, a straight or branched-chain C2 to C30 alkenyl, an aromatic or heteroaromatic ring with or without mono-, di-, or tri-substitutions of the ring, an acyl including a C1 to C30 alkyl or aromatic or heteroaromatic ring, an arylalkyl including straight or branched-chain C1 to C30 alkyl, or an aryloxyalkyl including straight or branched-chain C1 to C30 alkyl;

wherein when R^2 at X^2 is H and Q^2 is =O, R^1 is R^1 — Y^1 —A—with A being a direct link, Y^1 being —NH—, and R^1 being a straight or branched-chain alkyl group, the straight or branched-chain alkyl group is a C10 to C30 alkyl group; and

wherein the compound of formula (I) is not lysophosphatidic acid, phosphatidic acid, cyclic phosphatidic acid, alkenyl glycerolphosphate, dioctyl glycerol pyrophosphate, or N-palmitoyl-L-serine.

2. (canceled)

3. (currently amended) The compound according to claim 1, wherein the compound is from group (ii) and wherein

Q^1 is H_2 ;

Q^2 is $=O$;

Z^1 is O ; and

R^2 at both X^2 and X^3 is H are R^1-Y^1-A , with A being a direct link
and Y^1 being NH for each

4. (currently amended) The compound according to claim 3, wherein X^3 is $-NH_2$ and X^2 is $-NHR^1$ with R^1 at X^2 is being a straight chain C14 to C18 alkyl.

5. (currently amended) The compound according to claim 4, wherein R^1 at X^2 is a C14 alkyl.

6. (currently amended) The compound according to claim 4, wherein R^1 is at X^2 a C18 alkyl.

7. (currently amended) The compound according to claim 3, wherein X^3 is $-NHR^1$ with R^1 at X^3 is being an acetyl group and X^2 is $-NHR^1$ with R^1 at X^2 is being a C14 alkyl.

8-11 (canceled)

12. (original) A pharmaceutical composition comprising:
a pharmaceutically-acceptable carrier and
a compound according to claim 1.

13-34 (canceled)